The interaction of T-cell programmed cell death protein 1 (PD-1) with its tumour cell ligand can lead to decreases in antitumour response by these T cells, hence the use of anti-PD-1/PD-L1 antibodies for improving treatment response [47]. This evidence concerns the gene PDCD1 and neoplasm.